ChristopherJosephMelaniMD
Oncology • Suburb Maryland Fac, MDHematologic Oncology
Staff Clinician, Lymphoid Malignancies Branch, NCI
Dr. Melani is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
10 Center Drive
Building 10, Room 4N115
Suburb Maryland Fac, MD 20897- Is this information wrong?
Education & Training
National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2014 - 2017
Johns Hopkins UniversityResidency, Internal Medicine, 2011 - 2014
Drexel University College of MedicineClass of 2011
Certifications & Licensure
MD State Medical License 2014 - 2025
DC State Medical License 2014 - 2016- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society, 2011
Publications & Presentations
PubMed
- Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R.Rahul Lakhotia, Kieron Dunleavy, Jeremy S Abramson, Brian K Link, Bayard L Powell, Christopher Melani, Andrea N Lucas, Seth M Steinberg, Jonathan W Friedberg, Brad S K...> ;Blood Advances. 2023 Sep 26
- 1 citationsInterferon alfa-2b in patients with low-grade lymphomatoid granulomatosis and chemotherapy with DA-EPOCH-R in patients with high-grade lymphomatoid granulomatosis: an ...Christopher Melani, Kennichi Dowdell, Stefania Pittaluga, Kieron Dunleavy, Mark Roschewski, Joo Y Song, Sara Calattini, Jun-Ichi Kawada, David A Price, Pratip K Chatto...> ;The Lancet. Haematology. 2023 May 1
- 2 citationsDoxorubicin pharmacokinetics and toxicity in patients with aggressive lymphoma and hepatic impairment.Catherine Lai, Diane E Cole, Seth M Steinberg, Nicole Lucas, Eva Dombi, Christopher Melani, Mark Roschewski, Frank Balis, Brigitte C Widemann, Wyndham H Wilson> ;Blood Advances. 2023 Feb 28
- Join now to see all
Journal Articles
- End-of-Treatment and Serial PET Imaging Has Prognostic Value and Clinical Utility in Primary Mediastinal B-cell Lymphoma Following Dose-Adjusted EPOCH-R - Response to ...Mark Roschewski, Wyndham H Wilson, Christopher Melani, Haematologica
Abstracts/Posters
- Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvemen...Christopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Response-Adapted Therapy in HIV-Associated Diffuse Large B-Cell Lymphoma: Updated Results of a Prospective Phase II Study of Short-Course-EPOCH-RRChristopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 2 Study of Alemtuzumab Added to Dose-Adjusted EPOCH-R in Relapsed and Refractory Aggressive B-Cell LymphomasChristopher Melani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Phase 1b Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory B-Cell Lymphoma: Safety, Efficacy and Molecular Anal...61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Circulating Tumor DNA Dynamics during Therapy Predict Outcomes in Mantle Cell Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Major Survival Gain with Immunotherapy in Lymphomatoid GranulomatosisApril 5th, 2023
New Therapy Cures Cancer with Just One InjectionJanuary 8th, 2019
Adaptive Biotechnologies and Collaborators to Highlight Clinical Relevance of Measuring Residual Disease in Blood Cancers at ASH 2017December 8th, 2017
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
